Table 2.

Door‐to‐Needle Time and Clinical Outcomes in Post Hoc Analysis

Variable	Door‐to‐needle time <30 min	Door‐to‐needle time ≥30 min	P value	Median difference (95% CI)	OR (95% CI)
Probability of favorable neurological function, % (95% CI)	11.0% (10.3% to 11.6%)	6.6% (5.2% to 7.9%)	<0.001	1.7% (0.7% to 2.9%)
Door‐to‐ECMO time, min, median (IQR)	21 (15 to 28)	48 (43 to 69)	<0.001	−29 (−31 to −27)
Low‐flow time, min, median (IQR)	54 (45 to 63)	77 (70 to 90)	<0.001	−24 (−27 to −21)
Adverse events related to ECMO cannulation, n (%)	230 (19.2%)	27 (27.8%)	0.039		0.61 (0.39 to 0.98)
Amount of transfusion until ICU admission, mean, median (IQR)
Red blood cell, mL	210, 0 (0 to 0)	370, 0 (0 to 560)	0.017	0 (0 to 0)
Fresh frozen plasma, mL	160, 0 (0 to 0)	360, 0 (0 to 240)	0.056	0 (0 to 0)
Septicemia, n (%)	61 (6.7%)	0 (0.0%)	0.005		…
ECMO use, d, median (IQR)	3 (2 to 5)	2 (2 to 5)	0.052	1 (0 to 1)
Ventilator use, d, median (IQR)	2 (1 to 8)	2 (1 to 5)	0.039	0 (0 to 1)
Length of ICU stay, d, median (IQR)	2 (1 to 9)	2 (1 to 4)	0.026	1 (0 to 1)
Length of hospital stay, d, median (IQR)	2 (1 to 14)	2 (1 to 5)	0.044	0 (0 to 1)
In‐hospital survival, n (%)	259 (21.6%)	11 (11.3%)	0.017		2.15 (1.13 to 4.09)

ECMO indicates extracorporeal membrane oxygenation; ICU, intensive care unit; IQR, interquartile range; and OR, odds ratio.